All 18 COVID-19 patients hospitalized with moderate or severe symptoms who were administered the drug Amor-18 developed by Israeli biotech company Amorphical in a phase II clinical trial recovered and were discharged in a few days, the company announced Wednesday. Of the 19 individuals who were given a placebo, six had to be transferred to intensive care, and two died.
All 18 hospitalized individuals administered the treatment developed by Israeli biotech company Amorphical in a phase II trial recovered and were discharged in a few days.
Comments are closed.